PHAS Phasebio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

$2.00  +0.05 (2.56%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/18/2018
Outstanding shares:  48,089,983
Average volume:  1,110,481
Market cap:   $93,775,467
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    717224109
ISIN:        US7172241090
Sedol:      
Valuation   (See tab for details)
PE ratio:   -1.59
PB ratio:   11.43
PS ratio:   8.79
Return on equity:   235.12%
Net income %:   -1,108.74%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy